Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LEGEND BIOTECH CORPORATION

(LEGN)
  Report
Real-time Estimate Cboe BZX  -  03:04 2022-12-07 pm EST
54.59 USD   +1.16%
12/06UBS Initiates Coverage on Legend Biotech With Buy Rating, $66 Price Target
MT
12/06JPMorgan Adjusts Legend Biotech's Price Target to $65 From $61, Overweight Rating Kept
MT
11/22Legend Biotech : Extends Interim Product Supply Agreement with Janssen Pharmaceuticals, Inc - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults with Multiple Myeloma

09/27/2022 | 10:27am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.50% 176.9342 Delayed Quote.4.51%
LEGEND BIOTECH CORPORATION 1.42% 54.61 Delayed Quote.15.77%
All news about LEGEND BIOTECH CORPORATION
12/06UBS Initiates Coverage on Legend Biotech With Buy Rating, $66 Price Target
MT
12/06JPMorgan Adjusts Legend Biotech's Price Target to $65 From $61, Overweight Rating Kept
MT
11/22Legend Biotech : Extends Interim Product Supply Agreement with Janssen Pharmaceuticals, In..
PU
11/21Genscript Biotech Unit Gets US FDA Nod for Clinical Development of Small Cell Lung Canc..
MT
11/21Legend Biotech Gets FDA Clearance for Small Cell Lung Cancer Trial
DJ
11/21Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage..
BU
11/21Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Ext..
CI
11/07Legend Biotech Announces Participation in Upcoming Investor Conferences
AQ
11/04Legend Biotech Announces Participation in Upcoming Investor Conferences
BU
11/03Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Pr..
BU
More news
Analyst Recommendations on LEGEND BIOTECH CORPORATION
More recommendations
Financials (USD)
Sales 2022 139 M - -
Net income 2022 -396 M - -
Net cash 2022 349 M - -
P/E ratio 2022 -41,7x
Yield 2022 -
Capitalization 9 033 M 9 033 M -
EV / Sales 2022 62,4x
EV / Sales 2023 45,0x
Nbr of Employees 1 071
Free-Float 5,97%
Chart LEGEND BIOTECH CORPORATION
Duration : Period :
Legend Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEGEND BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 53,96 $
Average target price 68,22 $
Spread / Average Target 26,4%
EPS Revisions
Managers and Directors
Ying Huang Chief Executive Officer & Director
Lori Macomber Chief Financial Officer
Fang Liang Zhang Chairman
Guowei Fang SVP, Global Head-Research & Early Development
Liz Gosen Senior Vice President-Global Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
LEGEND BIOTECH CORPORATION15.77%9 033
VERTEX PHARMACEUTICALS44.63%80 039
REGENERON PHARMACEUTICALS, INC.19.62%79 831
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-34.04%32 589
GENMAB A/S23.38%29 957